| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 1g |
|
||
| Other Sizes |
| ln Vitro |
In order to produce a pseudo-starvation signal, aldolase cannot bind to FBP, which is how aldometanib (0-1000 nM; 2 hours) activates AMPK [1].
|
|---|---|
| ln Vivo |
In thin mice, aldometanib (oral; 0–10 mpk) lowers blood glucose levels [1]. In obese hyperglycemic rats, aldometanib (oral; 2–10 mpk; twice daily; for a week) reduces blood sugar and ameliorates fatty liver disease [1]. Non-alcoholic steatohepatitis and fatty liver disease are reduced by aldometanib [1]. In NASH mice, aldometanib (oral; 2mpk; twice-daily; for one month) decreases liver fibrosis [1]. C may live longer if administered oral (0–50 μM; 0–50 days) aldometanib. elegans by means of the lysosomal route [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: Mouse primary hepatocytes, MEFs cells Tested Concentrations: 0-1000 nM Incubation Duration: 2 h Experimental Results: Activated AMPK in mouse embryonic fibroblasts (MEFs) and mouse primary hepatocytes cells. Immunofluorescence[1] Cell Types: MEFs cells Tested Concentrations: 5 nM Incubation Duration: 2 h Experimental Results: Inhibited TRPVs and induces AXIN lysosomal translocation. |
| Animal Protocol |
Animal/Disease Models: Lean mice[1]
Doses: 0-10 mpk Route of Administration: Oral Experimental Results: diminished fasting blood glucose and improved glucose tolerance, promoted muscular TBC1D1 phosphorylation and glucose uptake. Animal/Disease Models: Obese hyperglycaemic mice[1] Doses: 2-10 mpk Route of Administration: po (oral gavage) twice (two times) daily, for a week Experimental Results: diminished blood glucose, lowered blood glucose in a muscular AMPK-dependent manner diminished hepatic TAG, improved insulin sensitivity, increased glucose disposal rates, inhibited TAG synthesis in liver and primary hepatocytes, diminished fat mass. Animal/Disease Models: NASH mice[1] Doses: 2 mpk Route of Administration: po (oral gavage) twice-daily, for a month Experimental Results: diminished histological scores used to describe the features of NASH, diminished apoptosis rate of hepatic cells, inhibited inflammatory responses in the liver of NASH mice and improved glucose tolerance of NASH mice. Animal/Disease Models: C. elegans[1] Doses: 0-50 μM Route of Administration: po (oral gavage) 0 -50 days Experimental Results: Promoted oxidative stress resistance and mitoch |
| References |
| Molecular Formula |
C27H43CL2IN2
|
|---|---|
| Molecular Weight |
593.454198122025
|
| Exact Mass |
592.184
|
| CAS # |
2904601-67-6
|
| PubChem CID |
165413044
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
32
|
| Complexity |
424
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCCN1C=C[N+](=C1C)CC2=C(C=CC=C2Cl)Cl.[I-]
|
| InChi Key |
QGSVKLIYXRLMTB-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C27H43Cl2N2.HI/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20-30-21-22-31(24(30)2)23-25-26(28)18-17-19-27(25)29;/h17-19,21-22H,3-16,20,23H2,1-2H3;1H/q+1;/p-1
|
| Chemical Name |
1-[(2,6-dichlorophenyl)methyl]-3-hexadecyl-2-methylimidazol-1-ium;iodide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (168.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6851 mL | 8.4253 mL | 16.8506 mL | |
| 5 mM | 0.3370 mL | 1.6851 mL | 3.3701 mL | |
| 10 mM | 0.1685 mL | 0.8425 mL | 1.6851 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
